Madopar Depot

Levodopa/Benserazide Hydrochloride, the active ingredient in Madopar Depot, is an antiparkinson agent presented as a prolonged‑release oral tablet for oral use. It treats Parkinson's disease and related Parkinsonian syndromes by increasing central dopamine levels.

GNH USA supplies Madopar Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Depot is an antiparkinson medication used to manage motor symptoms in Parkinsonian disorders.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: provides symptomatic relief of tremor, stiffness, and slowed movement. - Secondary Parkinsonism: helps control motor deficits when caused by drug‑induced or vascular factors.

Adverse reactions may occur with Madopar Depot and should be monitored.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or hypertension - Cardiac arrhythmias - Neuroleptic malignant syndrome - Anaphylactic or severe allergic reactions

When prescribing Madopar Depot, clinicians should consider several safety measures.

- Dose titration: adjust gradually under medical supervision. - Cardiovascular monitoring: watch for hypotension and arrhythmias. - Psychiatric assessment: monitor for hallucinations or mood changes. - Renal/hepatic function: consider dose adjustment in impairment. - Drug interactions: review concomitant medications for MAO‑B inhibitors. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Madopar Depot can interact with various medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Irreversible MAO‑B inhibitors (e.g., selegiline) without washout: severe hypertension. - Antipsychotics (e.g., haloperidol): may reduce antiparkinson efficacy. - Anticholinergics: may increase central side effects. - Sympathomimetics (e.g., epinephrine): may cause excessive hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - SSRIs/SNRIs: possible serotonin syndrome. - Carbonic anhydrase inhibitors (e.g., acetazolamide): may raise plasma levodopa. - Iron supplements: reduce levodopa absorption if taken together. - High‑protein meals: may decrease levodopa bioavailability.